Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 87Lymphoma, Non-Hodgkin 21Leukemia 18Lymphoma, Follicular 17Lymphoma, B-Cell, Marginal Zone 14Lymphoma 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma, Mantle-Cell 12Lymphoma, Large B-Cell, Diffuse 12Lymphoma, B-Cell 10Recurrence 7Leukemia, Myeloid, Acute 7Hodgkin Disease 7Waldenstrom Macroglobulinemia 6Leukemia, B-Cell 6Hematologic Neoplasms 6Burkitt Lymphoma 6Myelodysplastic Syndromes 5Multiple Myeloma 5Sezary Syndrome 4Mycosis Fungoides 4Leukemia, Hairy Cell 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Myeloproliferative Disorders 3Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, T-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3

Interventions

Rituximab 1Brentuximab Vedotin 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Infectious Mononucleosis × Bendamustine Hydrochloride × Other hematologic neoplasm × Clear all
NCT04138875 2022-06-23

A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

Yale University

Phase 2 Withdrawn
Other hematologic neoplasm

Infectious Mononucleosis, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡